A Lloyd's Emerging Risk Report
- Posted on 26 July
A new lease of life
Synthetic biology, the application of engineering principles to genetic modification is a market forecast to grow to $39bn by 2020. In recent years scientists have been applying engineering principles to biology, creating functions that do not exist in nature to prevent and treat disease, create materials and energy sources, make crops more resistant and even support space exploration.
As this market develops the risk profile is changing. Commercialisation and digitalisation of research are enabling faster adoption and with further developments on the horizon, it is critical for insurers to consider the associated risks and opportunities.
To help the Lloyd’s market understand this rapidly evolving technology, Lloyd’s has worked with Drs John Heap and Karen Polizzi of Imperial College London, who provided their independent opinion, to produce ‘A new lease of life’. The report also covers recent developments since the Lloyd’s 2009 report and commercial applications, including an overview of the associated risks.
The report is aimed at underwriters, brokers and exposure managers who are or will be exposed to synthetic biology, to encourage them to work with manufactures to support the responsible development of new technologies and solutions.
Download the report here
Share this article:
People also read
New competition - metasurfaces for defence and security
This themed competition is seeking proposals for innovative solutions that will pull ideas from recent breakthroughs in metasurface science into produ...
Global Biofoundry Meeting, London, June 2018
A meeting was held at Imperial College London on June 21st/22nd 2018, which gathered fifteenof the leading synthetic biology biofoundries from around the world to discuss current activities and exchange information on key capabilities and projects being developed by these groups.
If you missed the webinar you can catch up here https://synbiobeta.com/synbicite-webinarThe webinar highlighted findings from SynBioBeta’s 2018 Q2 inv...